An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases.
VERDICT
The label
Accumulation
read at $23.29
Denali Therapeutics Inc. holds its Accumulation at $23.29.
PHPhase · the trend structure carries the Accumulation label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · screen not yet scored
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-07-19
Phase
Accumulation
Quantitative state
The statistical read favours the buyers, held for 1 days
Price
$23.29
Valuation
N/A trailing · -9.37 forward price to earnings
Values screen
Not scored· score 70.0
Beta
0.96
OPPORTUNITY
The opportunity · what the numbers say it is worth
Read at
$23.29
N/A P/E · -9.37 fwd
Our fair value
$35.00
50% discount
Analyst target (avg)
$35.00
+50% to current
Target low $25.00Analyst target rangeTarget high $42.00
▲ current $23.29 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$23.29
you are here
Conservative
$25.00
+7%
Analyst avg
$35.00
+50%
Our fair value
$35.00
+50%
Analyst high
$42.00
+80%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Profit margin
0.00%
Debt to equity
4.32
Analyst consensus
Strong Buy · 16 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This security has not been fully scored against the values screen yet.
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is of its assets, above the one-third ceiling the screen allows.Fail
Interest-bearing cashInterest-bearing cash and securities are of assets, above the one-third limit.Fail
ReceivablesMoney owed to the company is of assets, above the 49% limit.Fail
Revenue purity of revenue comes from non-compliant sources, over the 5% line.Fail
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Developing drugs for brain diseases is like drilling for oil in the dark. Denali Therapeutics spends heavily on early stage candidates for neurodegenerative conditions yet shows zero profit margin and a negative fifty per cent return on equity. With no usable financial ratios the ethical screen returns insufficient data, so the opportunity rating stays at none despite analysts clustering around a thirty five dollar target.
The business sits in a high burn sector where forward earnings sit at a negative nine point four times multiple because losses continue. Strong buy ratings from sixteen analysts reflect pipeline hope rather than current delivery, but the lack of basic ratio visibility blocks any further assessment under our rules.
Risk sits in execution and capital needs, typical for clinical stage biotechnology where one failed trial can wipe out years of spend. Currency or market swings matter less here than the simple absence of track record data. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
PEERS
Related securities · others in DNLI's space worth a look
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
DNLI trades on Nasdaq. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 7.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 17% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (15 analysts) rates it strong buy, with a mean price target of $34. Entered 2026-07-26 · Markup
JOURNAL
The dated journal · newest first, never edited
2026-07-26Markup$23.29+7.5%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 7.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 17% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (15 analysts) rates it strong buy, with a mean price target of $34.
2026-07-18Markup$21.66+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 17% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (15 analysts) rates it strong buy, with a mean price target of $34.
2026-07-03Markup$21.66+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markup$21.66Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
RETURNS
What holding actually paid · price plus dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$19.67
+3.5%
·
$1,035
+3.5%
2 months
$19.23
+5.9%
·
$1,059
+5.9%
3 months
$20.70
-1.7%
·
$983
-1.7%
6 months
$17.37
+17.2%
·
$1,172
+17.2%
1 year
$15.26
+33.4%
·
$1,334
+33.4%
2 years
$21.02
-3.2%
·
$968
-3.2%
3 years
$30.52
-33.3%
·
$667
-33.3%
5 years
$75.00
-72.9%
·
$271
-72.9%
Historical returns from market close data. Past performance does not guarantee future results.
SEALED
This entry now belongs to the ledger. Whatever DNLI does next, these words stay.
Denali Therapeutics Inc. · DNLI · Accumulation · $23.29
Recorded 2026-07-19 · before the outcome · scored mechanically
